Organic Active Ingredients TRIZ Cases

Wet Tg above body temperature helps polyesteramide copolymers resist aqueous plasticization and deliver more stable, extended drug release.

Topical alpha-adrenergic antagonists reduce pupil diameter and improve vision while minimizing burning sensation and daytime eye redness.

Cysteamine-based compounds lower Muc5ac and reduce airway mucus buildup, improving mucociliary clearance in obstructive lung disease.

Targeted nanoparticles deliver IRF5 and IKKβ nucleotides to reprogram tumor-associated macrophages into tumoricidal cells while limiting systemic toxicity.

siRNA against plasminogen, delivered by lipid nanoparticles, reduces fibrinolysis to stabilize clots and support longer-term bleeding prophylaxis.

A plant-derived DHA-rich lipid blend improves oxidative stability by limiting EPA and using ester processing to reduce contamination.

Fine metformin powder is formed into spherical clusters to prevent agglomeration while preserving dispersibility and lung deposition for IPF treatment.

Elevated TML and TMAO levels guide CKD and heart failure risk assessment and support pathway-inhibiting treatment beyond intermittent dialysis.

Safe inorganic nitrate dosing lowers oxygen consumption and improves endurance while avoiding hypotension and methemoglobinemia.

pH adjustment before freeze-drying helps salfaprodil injection avoid layering, precipitation, and poor re-solubility while improving stability.

Selective ALK5-blocking acetamide derivatives address inadequate TGF-β inhibition to reduce chronic inflammation and fibrosis.

CX3CR1-defective HSPCs speed microglia engraftment and expansion, improving brain delivery of neuroprotective agents for neurological disease.

Higher-molecular-weight excipients prevent tablet blooming while improving Compound A stability, disintegration, friability, and bioavailability.

A chitosan-glycerol hydrogel with Acacia nilotica improves moisture retention and antimicrobial protection to speed diabetic wound healing.

An elastic, buoyant bladder insert stays retained without urethral voiding or ureter entry, enabling prolonged drug release with less discomfort.

Barrier-coated clonidine resin particles deliver 24-hour oral release, smoothing plasma peaks to reduce daytime sedation and dosing frequency.

Ex vivo PDCD-1 gene cleavage in T cells reduces exhaustion and systemic toxicity while sustaining anti-tumor activity.

Ribose-modified cap analogs improve mRNA stability and translation efficiency while reducing decapping and extending protein expression.

Solid crystalline oral brexanolone improves absorption and fed-fasted consistency, enabling effective CNS treatment without IV hospitalization.

Heparin blocks viral surface proteins and N-acetylcysteine disrupts capsid bonds to reduce respiratory virus infectivity.

Specific lipid particles enable endocytic delivery of therapeutic or diagnostic cargo to T-cell malignant tumor cells while limiting uptake by normal cells.

Controlling granule size and homogeneity helps high-amino-acid formulations melt in the mouth, dissolve in water, and reduce residue.

A surfactant-carrier solid dispersion self-emulsifies in GI fluids to improve solubility, bioaccessibility, and oral absorption.

A volatile and non-volatile solvent blend treats erectile dysfunction without GTN, avoiding headache risks and nitrate contraindications.

Monoclonal antibodies neutralize endothelin-1 to delay glomerular disease progression and reduce fibrosis in Alport syndrome.

A multi-source polysaccharide composition regulates Th1/Th2 balance to inhibit ovalbumin-induced immune stress with fewer side effects.

Co-administering bupropion with dextromethorphan slows metabolism, extends plasma exposure, reduces dosing frequency, and lowers adverse events.

Small molecules disrupt zinc-mediated tau phase separation and dissolve condensates, addressing a key bottleneck in tau aggregation therapy.

Porphyrin dimer PDT primes tumor immunogenicity before checkpoint inhibition, improving control of recurrent or metastatic esophageal cancer.

A bilayer ibuprofen tablet pairs immediate and sustained release to deliver fast pain relief and maintain effective levels for 24 hours.

Using Boc deprotection and controlled crystallization, this case improves furazanobenzimidazole yield, purity, and salt processability.

Minimal processing keeps the amnion, chorion, and spongy layer intact to preserve growth factors for wound healing on irregular wounds.

Hydrophilic Cordylutene derivatives solve lutein solubility limits while absorbing blue light and reducing oxidative stress in ocular tissues.

Selective PDE4 inhibition with orismilast reduces inflammatory cytokines, pain, and disease progression in pyoderma gangrenosum.

Minor cannabinoids combined with THC and CBD modulate NMDA, glutamate, and CGRP to reduce migraine and fibromyalgia pain with fewer THC side effects.

Chemically modified RNAi oligonucleotides target LPA mRNA in the liver to overcome inadequate Lp(a) reduction and slow related disease progression.

Timed vaccination before and during cladribine therapy helps control autoimmune symptoms while lowering severe infection risk.

Combining cannabinoids with VR sensory stimuli and response feedback helps address PTSD, anxiety, and learning disorders.

Stable polymorphic forms of a small-molecule GLP-1R agonist improve purification, processing, and oral drug suitability for diabetes treatment.

A macrocyclic ligand recruits cyclophilin A to Ras, creating a new pocket that blocks effector binding and suppresses oncogenic signaling.

Low-dose stressed-plant terpenoid and cannabinoid blends target reward signaling to ease withdrawal with lower side-effect and self-addiction risk.

Combining NAMPT inhibitors with HDAC8 and/or SIRT6 inhibitors boosts AML cell apoptosis and reduces self-renewal to address poor survival.

Small-molecule GPR146 inhibitors replace complex biologics while lowering LDL cholesterol, triglycerides, and hypertension with minimal cytotoxicity.

Linking cannabinoids into polymer matrices improves aqueous delivery and storage stability for sustained use in coatings, fibers, and patches.

Stable-isotope SCFA tracing with blood compartmental analysis overcomes absorption and liver metabolism to measure true colonic production.

CHAMPs link KRAS(G12D) and HSP90 to drive tumor-selective degradation while reducing off-target tissue effects and resistance.

A 40-60% SBECD aqueous bendamustine formulation maintains refrigerated stability without lyophilization, reconstitution, or organic solvents.

Aerosolized clofazimine uses controlled particle size and surfactants to improve lung delivery for NTM infection while reducing systemic toxicity.

MLPSCs, exosomes, or conditioned media improve partial cell reprogramming by modulating inflammation and preserving cell identity.

A dual TRKA G667C and FLT3 inhibitor addresses resistance mutations and shows synergistic tumor cell inhibition when combined with chidamide.

Selective 1H-pyrrolo[2,3-c]pyridine CSF-1R inhibitors improve combination therapy compatibility by limiting CYP interactions and off-target effects.

Targeted CYP7A1 RNAi silences liver transcripts to stabilize bile acid homeostasis and address PSC progression beyond ursodeoxycholic acid.

Fluid flow around a trough-mounted electrode clears electrolysis bubbles, stabilizing voltage and drug delivery in implantable iontophoresis reservoirs.

Artificial plasmids trigger in vivo exosome formation to deliver multi-target siRNA with lower production burden and targeted cancer therapy.

Selective mPGES-1 inhibition with pyrimidine derivatives improves oral absorption and solubility while reducing gastric toxicity in anti-inflammatory treatment.

New small-molecule EED inhibitors use structural changes to overcome PRC2 inhibitor resistance and improve treatment potential in tumors and autoimmune disorders.

Microbial strains and lipopolysaccharides modulate subject metabolite levels for personalized disease screening and treatment.

Targeted deuterium substitution slows aminothiazole metabolism, extending half-life and improving HSV-1 and HSV-2 antiviral efficacy.

Sequential NR5A factor expression and cAMP stimulation raise sex steroid output from stem cells for HPG axis rebalancing.

A hydrophilic crosslinked microsphere matrix controls swelling, suspension stability, and elasticity for precise permanent vascular occlusion.

Once-daily EYP001 dosing cuts pruritus versus twice-daily FXR agonist use while preserving efficacy in chronic liver disease treatment.

Heterocyclic pyrimidopyran compounds broaden KRAS targeting beyond G12C to pan-KRAS mutations and amplifications for tumor therapy.

Combining kynurenine with antigen-presenting cells improves immune tolerance to lower blood glucose in T1D and prevent hair loss in AA.

Quinazoline compounds block the SOS1-KRAS interaction to inhibit oncogenic signaling and improve therapeutic potential in KRAS-driven cancers.

A hydrolysable linker carries two or more oligonucleotides, balancing circulation stability with controlled release for stronger gene silencing.

Crystalline CDK inhibitor forms improve solubility and stability while enabling selective CDK2 inhibition with lower CDK1-linked toxicity.

Small-molecule polycyclic sulfones mimic GDNF signaling to cross the blood-brain barrier and deliver neuroprotective effects without invasive delivery.

Selective bicyclic urea compounds inhibit the JAK2 V617F mutant while preserving essential JAK2 functions needed for normal signaling.

A silicate-carrier self-emulsifying solid dispersion improves solubility, bioaccessibility, and oral absorption of poorly soluble actives.

A high starting dose of rivoceranib treats severe recurrent or metastatic ACC by slowing progression and extending survival with tolerable adverse events.

Targeting PAX2 with siRNA or oligonucleotides while increasing DEFB1 enables earlier, more precise breast cancer intervention.

Compounds targeting the BCL6 BTB domain block corepressor recruitment to suppress malignant B cell proliferation and treat BCL6-driven cancers.

Benzoic acid salts such as sodium benzoate improved long COVID cognitive function over 24 weeks without reported side effects.

A spray-dried nasal powder with disaccharide and dextrin carriers avoids freezing and improves opioid antagonist absorption for overdose treatment.

A hyaluronic acid, adhesive, and low-dose antibiotic gel shortens mucosal wound coverage time while improving stability and complication prevention.

Sulcardine shortens the JTp interval to offset QTc prolongation and help prevent ventricular tachycardia and Torsades de Pointes.

Targeting CD19 with obexelimab reduces B-cell-driven hemolysis in warm AIHA while avoiding the broad risks of steroids and immunosuppressants.

Defined chlorpheniramine and oxymetazoline ranges improve rhinitis symptom relief while avoiding trial-heavy ratio optimization.

Semifluorinated alkane carriers improve prostaglandin and antiandrogen delivery into the pilosebaceous unit while reducing cosolvent irritation.

Zeolite absorbs ammonia while Lactobacilli inhibit Helicobacter, reducing urease activity without antibiotic resistance or dysbiosis.

CF3CN derivatives use zein/lactoferrin nanoparticles and liposomes to raise oral bioavailability and brain drug concentration for AD treatment.

A tidal peritoneal dialysis approach regenerates hypertonic dialysate with sugar concentrate to sustain osmotic pressure and fluid removal.

Acid-adjusted fospropofol dosage forms improve oral bioavailability and reduce inter-subject variability for more consistent delivery.

PARG-inhibiting sulfonamides prolong PARylation at DNA lesions, block repair, and sensitize cancer cells to radiation and DNA-damaging agents.

A bifunctional heterocyclic compound recruits E3 ligase to degrade G12V mutant KRAS, addressing limited efficacy in pancreatic and lung cancer.

Benzimidazole compounds target conserved viral proteases to treat coronavirus infections while helping address mutation-driven drug resistance.

Scalable multi-gram synthesis of biheteroaryl antiviral compounds supports reproducible HBV and HDV treatment development with improved therapy options.

A natural compound suppresses AURKA protein expression in a dose-dependent way, aiming to avoid off-target kinase effects and resistance.

Azetidine compounds inhibit the HSV helicase-primase complex to treat resistant and TK-deficient infections with fewer adverse effects.

Soft minute projections stretch and thin skin or oral mucosa to speed local anesthetic and antihistamine absorption without puncture.

Biopterin compounds inhibit iNOS to lower extracellular brain glutamate, reduce lactate, and protect neurons after excitotoxic injury.

Cyclophilin A mediates a high-affinity ternary complex that creates a new Ras binding pocket and blocks downstream effector interactions.

Stepwise intermediates and Vilsmeier chemistry improve ruxolitinib yield and purity without excessive process complexity.

Targeted ceramides reinforce the dermal-epidermal junction to improve cell adhesion, hydration, firmness, and visible skin aging signs.

A non-aqueous tylvalosin tartrate injectable uses DMSO, propylene glycol, benzyl alcohol, and antioxidant adjuvants to limit degradation.

OSA starch stabilizes high-fat spray-dried emulsions, keeping free fat low while raising solids content and reducing dilution energy.

A novel linker controls DAR in HER2 antibody-drug conjugates to reduce aggregation, improve plasma stability, and limit toxicity.

Novel isoxazole compounds selectively inhibit LPA1 receptor activity to address inadequate fibrosis treatment and slow disease progression.

Non-steroidal finerenone addresses heart failure treatment limits under CYP3A4 inhibitor or inducer use while lowering hospitalization and death risk.

By degrading Helios via the Cereblon E3 ligase complex, these oxoisoindoline compounds boost antitumor immunity while limiting autoimmune risk.